# A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD

> **NCT00485849** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 12 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine Hydrochloride

## Key facts

- **NCT ID:** NCT00485849
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2007-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485849, "A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00485849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*